Quarterly Report — Form 10-Q
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.17M
2: EX-10.8 Material Contract HTML 70K
3: EX-10.9 Material Contract HTML 67K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
14: R1 Document and Entity Information HTML 76K
15: R2 Consolidated Balance Sheets HTML 91K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 32K
17: R4 Consolidated Statements of Net Loss and HTML 55K
Comprehensive Loss
18: R5 Consolidated Statements of Changes in HTML 81K
Stockholders' Equity
19: R6 Consolidated Statements of Cash Flows HTML 84K
20: R7 Organization and Description of Business HTML 23K
21: R8 Basis of Presentation HTML 27K
22: R9 Summary of Significant Accounting Policies HTML 71K
23: R10 Net Loss Per Share HTML 45K
24: R11 Accrued Liabilities HTML 38K
25: R12 License Agreements and Commitments HTML 157K
26: R13 Stockholders' Equity HTML 27K
27: R14 Share-Based Compensation HTML 90K
28: R15 Related Party Transactions HTML 23K
29: R16 Income Taxes HTML 25K
30: R17 Other Benefits HTML 22K
31: R18 Summary of Significant Accounting Policies HTML 86K
(Policies)
32: R19 Summary of Significant Accounting Policies HTML 57K
(Tables)
33: R20 Net Loss Per Share (Tables) HTML 43K
34: R21 Accrued Liabilities (Tables) HTML 37K
35: R22 License Agreements and Commitments (Tables) HTML 145K
36: R23 Share-Based Compensation (Tables) HTML 82K
37: R24 Basis of Presentation (Details) HTML 26K
38: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 21K
Operating Leases (Details)
39: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 38K
Value Measurement (Details)
40: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 21K
Segment (Details)
41: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 51K
Recently issued accounting pronouncements
(Details)
42: R29 NET LOSS PER SHARE - Basic and diluted (Details) HTML 33K
43: R30 NET LOSS PER SHARE - Anti-dilutive securities HTML 21K
(Details)
44: R31 Accrued Liabilities (Details) HTML 32K
45: R32 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 52K
MabVax License Agreement (Details)
46: R33 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 98K
Agreement (Details)
47: R34 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 43K
agreements (Details)
48: R35 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 60K
agreements (Details)
49: R36 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 29K
(Details)
50: R37 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 39K
maturities (Details)
51: R38 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 24K
and discount rate (Details)
52: R39 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 38K
Preferred Stock (Details)
53: R40 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 70K
non-employees, Stock (Details)
54: R41 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 71K
(Details)
55: R42 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 29K
56: R43 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 40K
57: R44 SHARE-BASED COMPENSATION - Stock option expense HTML 29K
(Details)
58: R45 SHARE-BASED COMPENSATION - Stock option activity HTML 62K
(Details)
59: R46 SHARE-BASED COMPENSATION - Stock option HTML 26K
unrecognized compensation (Details)
60: R47 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 61K
Activity (Details)
61: R48 Related Party Transactions (Details) HTML 33K
62: R49 INCOME TAXES - Expense (Details) HTML 33K
63: R50 INCOME TAXES - Uncertain tax positions (Details) HTML 21K
64: R51 Other Benefits (Details) HTML 23K
66: XML IDEA XML File -- Filing Summary XML 115K
13: XML XBRL Instance -- ymab-20200930x10q_htm XML 1.37M
65: EXCEL IDEA Workbook of Financial Reports XLSX 75K
9: EX-101.CAL XBRL Calculations -- ymab-20200930_cal XML 101K
10: EX-101.DEF XBRL Definitions -- ymab-20200930_def XML 420K
11: EX-101.LAB XBRL Labels -- ymab-20200930_lab XML 984K
12: EX-101.PRE XBRL Presentations -- ymab-20200930_pre XML 758K
8: EX-101.SCH XBRL Schema -- ymab-20200930 XSD 136K
67: JSON XBRL Instance as JSON Data -- MetaLinks 273± 408K
68: ZIP XBRL Zipped Folder -- 0001558370-20-012905-xbrl Zip 300K
‘EXCEL’ — IDEA Workbook of Financial Reports
This is an IDEA Workbook.
10 Subsequent Filings that Reference this Filing
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent
2/29/24 Y-mAbs Therapeutics, Inc. S-8 2/29/24 4:185K Toppan Merrill Bridge/FA
2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA
3/30/23 Y-mAbs Therapeutics, Inc. S-8 3/30/23 4:168K Toppan Merrill Bridge/FA
3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA
3/01/22 Y-mAbs Therapeutics, Inc. 10-K 12/31/21 93:10M Toppan Merrill Bridge/FA
11/04/21 Y-mAbs Therapeutics, Inc. 10-Q 9/30/21 76:7.4M Toppan Merrill Bridge/FA
8/09/21 Y-mAbs Therapeutics, Inc. 10-Q 6/30/21 76:7.2M Toppan Merrill Bridge/FA
3/01/21 Y-mAbs Therapeutics, Inc. 10-K 12/31/20 84:9.6M Toppan Merrill Bridge/FA
2/18/21 Y-mAbs Therapeutics, Inc. 424B5 1:2.2M Toppan Merrill-FA
2/17/21 Y-mAbs Therapeutics, Inc. 424B5 1:2.2M Toppan Merrill-FA
|
3 Previous Filings that this Filing References
↑Top
Filing Submission 0001558370-20-012905 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Thu., May 2, 11:58:42.1am ET 
